The Hypoxia Inducible Factor 1 Alpha pipeline drugs market research report outlays comprehensive information on the Hypoxia Inducible Factor 1 Alpha targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Hypoxia Inducible Factor 1 Alpha pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Ophthalmology, Gastrointestinal, and Dermatology which include the indications Oncology, Melanoma, Ophthalmology, Glaucoma, Oral Mucositis, Liver Failure (Hepatic Insufficiency), Diabetic Foot Ulcers, and Dermatitis (Eczema). It also reviews key players involved in Hypoxia Inducible Factor 1 Alpha targeted therapeutics development with respective active and dormant or discontinued products.
The Hypoxia Inducible Factor 1 Alpha pipeline targets constitutes close to 19 molecules. Out of which, approximately 17 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 3, 2, 9, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Hypoxia Inducible Factor 1 Alpha overview
Hypoxia-inducible factor 1-alpha is a subunit of a heterodimeric transcription factor encoded by the HIF1A gene. It plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. It activates the transcription of erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor and HILPDA under hypoxia condition.
For a complete picture of Hypoxia Inducible Factor 1 Alpha’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
